TrialPath

Find a study

Match me to a study

207 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

148 studies on the map

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — University of Alabama at Birmingham, BirminghamA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Banner Alzheimer?s Institute, PhoenixPragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults — University of Alabama at Birmingham, BirminghamA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) — Chandler Clinical Trials, LLC, ChandlerA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Healthy Brain Clinic, Long BeachA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Imaging Endpoints, ScottsdaleA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Local Institution - 2609, ChandlerCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, Huntsville"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Fullerton Neurology and Headache Center, FullertonScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — University of Alabama at Birmingham, BirminghamA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Banner Alzheimer's Institute, PhoenixA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New Haven[18F]PI-2620 Phase 3 Histopathological Study — Barrow Neurological Institute, PhoenixMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Advanced Research Center, Inc., AnaheimA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — Barrow Neurological Institute, PhoenixA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) — Collaborative Neuroscience Network - CNS, Los AlamitosA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease — Irvine Center for Clinical Research /ID# 277752, IrvineA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamA First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease — K2 Medical Research, LLC, MaitlandPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Local Institution - 1227, ChandlerA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) — Gilbert Neurology Partners/CCT Research, GilbertClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Behavioral Research Specialists, LLC, GlendaleStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — The Ohio State University (OSU) Wexner Medical Center, ColumbusPreventing Alzheimer's With Cognitive Training — University of Florida, GainesvilleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD — Clinical Trial Site, La JollaSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaFerritin and Iron Burden in SAH sIRB — Univesity of Iowa Hospital and Clinics, Iowa CitySex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease — Mayo Clinic, JacksonvilleA Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment — University of California - San Diego, La JollaRepurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Cedars-Sinai Medical Center, Los AngelesExploration of an Online Education Program to Support Caregivers' Knowledge Transfer — Texas Christian University, Fort WorthEpidemiology and Biomarker Study in Alzheimer's Disease — Care Access - Houston, HoustonAV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) — Comprehensive Center for Brain Health, Boca RatonEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockAβ Dynamics in LLMD — NYU Langone Health, New YorkFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesA Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK — Washington University in St. Louis, St LouisComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoTREAD: Time Restricted Eating Intervention for Alzheimer's Disease — Shiley Marcos Alzheimer's Disease Center, San DiegoDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiProbiotic Administration for Adolescent Depression — UCSF, San FranciscoPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBehavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care — Ralph H. Johnson VA Medical Center, Charleston, SC, CharlestonLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinMood Effects of Serotonin Agonists: Depression — University of Chicago, ChicagoNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaGlutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine — Emory University, AtlantaExamining the Effects of Estradiol on Neural and Molecular Response to Reward — University of North Carolina at Chapel Hill, Chapel HillNeural Circuit Effects of Ketamine in Depression — Icahn School of Medicine at Mount Sinai, New YorkCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaPET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. — Stony Brook University: Dept of Psychiatry, Stony BrookModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, Atlanta[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaSynaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — McLean Hospital, BelmontCreatine for Depressed Male and Female Methamphetamine Users — Montana State University College of Nursing (Missoula campus), MissoulaThe Role of mGluR5 in CBT-I — Stony Brook University: Dept of Psychiatry, Stony BrookAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder — Athinoula A. Martinos Center for Biomedical Imaging, CharlestownPrefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth — University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, CincinnatiConfirmatory Efficacy Trial of Attention Bias Modification for Depression — Institute for Mental Health Research, AustinLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaDBS for Depression — Zucker Hillside Hospital, QueensACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine — University of Pennsylvania, PhiladelphiaOvarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression — University of North Carolina, Chapel Hill, Chapel HillPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontRNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) — Mayo Clinic in Rochester, RochesterSerotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures — Wake Forest University Health Sciences, Winston-SalemRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesEstablishing Mobile Transcranial Magnetic Stimulation — Medical Univerity of South Carolina, CharlestonEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaAdjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression — The University of Texas Health Science Center at Houston, HoustonPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — Johns Hopkins Center for Psychedelic and Consciousness Research, BaltimoreGlutathione, Brain Metabolism and Inflammation in Alzheimer's Disease — Baylor College of Medicine, HoustonDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, Memphis

Showing the 150 nearest — narrow your filters for fewer, closer studies.